KR102058259B1 - 인슐린 의존성 당뇨병의 치료에 유용한 줄기 세포 및 췌장 세포 - Google Patents

인슐린 의존성 당뇨병의 치료에 유용한 줄기 세포 및 췌장 세포 Download PDF

Info

Publication number
KR102058259B1
KR102058259B1 KR1020157000845A KR20157000845A KR102058259B1 KR 102058259 B1 KR102058259 B1 KR 102058259B1 KR 1020157000845 A KR1020157000845 A KR 1020157000845A KR 20157000845 A KR20157000845 A KR 20157000845A KR 102058259 B1 KR102058259 B1 KR 102058259B1
Authority
KR
South Korea
Prior art keywords
cells
pancreatic
cell
insulin
reprogrammed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157000845A
Other languages
English (en)
Korean (ko)
Other versions
KR20150036059A (ko
Inventor
윌리엄 엘. 러스트
Original Assignee
세라시스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세라시스, 인코포레이티드 filed Critical 세라시스, 인코포레이티드
Publication of KR20150036059A publication Critical patent/KR20150036059A/ko
Application granted granted Critical
Publication of KR102058259B1 publication Critical patent/KR102058259B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • C12N5/0678—Stem cells; Progenitor cells; Precursor cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/117—Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1329—Cardiomyocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/22—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
KR1020157000845A 2012-06-26 2013-06-24 인슐린 의존성 당뇨병의 치료에 유용한 줄기 세포 및 췌장 세포 Active KR102058259B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664259P 2012-06-26 2012-06-26
US61/664,259 2012-06-26
PCT/US2013/047243 WO2014004341A1 (en) 2012-06-26 2013-06-24 Stem cells and pancreatic cells useful for the treatment of insulin-dependent diabetes mellitus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197036838A Division KR102174581B1 (ko) 2012-06-26 2013-06-24 인슐린 의존성 당뇨병의 치료에 유용한 줄기세포 및 췌장 세포

Publications (2)

Publication Number Publication Date
KR20150036059A KR20150036059A (ko) 2015-04-07
KR102058259B1 true KR102058259B1 (ko) 2019-12-23

Family

ID=48746139

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157000845A Active KR102058259B1 (ko) 2012-06-26 2013-06-24 인슐린 의존성 당뇨병의 치료에 유용한 줄기 세포 및 췌장 세포
KR1020197036838A Active KR102174581B1 (ko) 2012-06-26 2013-06-24 인슐린 의존성 당뇨병의 치료에 유용한 줄기세포 및 췌장 세포

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197036838A Active KR102174581B1 (ko) 2012-06-26 2013-06-24 인슐린 의존성 당뇨병의 치료에 유용한 줄기세포 및 췌장 세포

Country Status (16)

Country Link
US (2) US9968639B2 (enExample)
EP (2) EP2864473B1 (enExample)
JP (2) JP6386453B2 (enExample)
KR (2) KR102058259B1 (enExample)
CN (2) CN113265370A (enExample)
AU (2) AU2013280698B2 (enExample)
BR (1) BR112014031676A2 (enExample)
CA (1) CA2876677C (enExample)
DK (1) DK2864473T3 (enExample)
EA (2) EA201992135A1 (enExample)
ES (1) ES2745704T3 (enExample)
IL (2) IL236346B (enExample)
IN (1) IN2015DN00281A (enExample)
PT (1) PT2864473T (enExample)
SG (1) SG11201408717XA (enExample)
WO (1) WO2014004341A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106467918B (zh) * 2015-08-18 2020-07-31 中国科学技术大学先进技术研究院 一种基于人皮肤细胞的胰岛素分泌细胞的诱导方法及应用
CN105434471A (zh) * 2015-11-26 2016-03-30 深圳爱生再生医学科技有限公司 治疗糖尿病的干细胞制剂及其制备方法
KR20250048481A (ko) * 2018-02-09 2025-04-08 세라시스, 인코포레이티드 당뇨병을 치료하기 위한 췌장 세포 및 이를 생성하는 방법
AU2019360857A1 (en) * 2018-10-15 2021-06-03 Evia Life Sciences Inc. Method for producing stem/precursor cells, by using low molecular weight compound, from cells derived from endodermal tissue or organ
KR20220113389A (ko) * 2019-12-11 2022-08-12 고쿠리츠다이가쿠호우진 도쿄다이가쿠 Mycl 의 일과성 발현에 의한 증식 가능한 췌도 전구 세포형 세포의 유도와 인슐린 양성 세포로의 분화 유도
US20220409855A1 (en) 2021-06-29 2022-12-29 Staffan Holmin Methods of delivering cells and therapeutic agents to organs and extravascular sites
WO2023199113A1 (en) 2022-04-15 2023-10-19 Smartcella Solutions Ab COMPOSITIONS AND METHODS FOR EXOSOME-MEDIATED DELIVERY OF mRNA AGENTS
WO2024163938A1 (en) 2023-02-03 2024-08-08 Seraxis, Inc. Therapeutic cells and methods relating to the same
WO2025029826A1 (en) 2023-07-31 2025-02-06 Seraxis, Inc. Modified therapeutics cells and methods relating to the same

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861313A (en) * 1995-06-07 1999-01-19 Ontogeny, Inc. Method of isolating bile duct progenitor cells
AU2376200A (en) 1999-01-07 2000-07-24 Incyte Pharmaceuticals, Inc. Insulin-synthesis genes
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
US20030082155A1 (en) 1999-12-06 2003-05-01 Habener Joel F. Stem cells of the islets of langerhans and their use in treating diabetes mellitus
CA2392615A1 (en) 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
JP2005537803A (ja) 2002-09-06 2005-12-15 アムサイト インコーポレーティッド Ｃｄ５６陽性ヒト成体膵臓内分泌前駆細胞
WO2004113512A2 (en) 2003-06-20 2004-12-29 Vrije Universiteit Brussel Method of generating islet beta-cells from exocrine pancreatic cells
JP2008500809A (ja) * 2004-03-09 2008-01-17 ライフスキャン・インコーポレイテッド インスリン産生細胞を発生させるための方法
US20060029987A1 (en) 2004-08-06 2006-02-09 Applera Corporation Diagnosis of pancreatic cancer by using pancreatic targets
US7807459B2 (en) 2005-09-27 2010-10-05 Reneuron, Inc. EphA4-positive human adult pancreatic endocrine progenitor cells
CN101553245A (zh) * 2006-07-19 2009-10-07 佛罗里达大学研究基金会有限公司 用于细胞重编程的组合物及其用途
WO2008112278A2 (en) 2007-03-12 2008-09-18 The Trustees Of Columbia University In The City Of New York Methods and compositions for modulating insulin secretion and glucose metabolism
EP2205724B1 (en) * 2007-11-09 2016-04-27 RNL Bio Co., Ltd. Method for isolating and culturing adult stem cells derived from human amniotic epithelium
WO2009128533A1 (ja) 2008-04-18 2009-10-22 国立大学法人名古屋大学 間葉系幹細胞およびその生産方法
US20110158961A1 (en) * 2008-05-09 2011-06-30 The University Court Of The University Of Glasgow Materials and methods relating to cell based therapies
US9683215B2 (en) * 2008-08-22 2017-06-20 President And Fellows Of Harvard College Methods of reprogramming cells
EP2641911A3 (en) * 2008-12-23 2014-01-01 Vivoscript, Inc. Compositions and methods for re-programming cells without genetic modification
US20120263689A1 (en) * 2009-09-10 2012-10-18 The Salk Institute For Biological Studies Adipose-derived induced pluripotent stem cells
EP3498825A1 (en) * 2010-05-12 2019-06-19 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
SG187830A1 (en) * 2010-08-22 2013-03-28 Univ Ramot Induced pluripotent stem cells derived from human pancreatic beta cells
RU2673946C1 (ru) * 2010-08-31 2018-12-03 Янссен Байотек, Инк. Дифференцирование плюрипотентных стволовых клеток
EP2616539A1 (en) * 2010-09-15 2013-07-24 Ramot at Tel-Aviv University Ltd. Methods of expanding and redifferentiating islet beta cells
US20120135015A1 (en) * 2010-09-28 2012-05-31 Baylor Research Institute Induction of Pancreatic Stem Cells by Transient Overexpression of Reprogramming Factors and PDX1 Selection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CELL RESEARCH, vol.19(4), pp.429~438(2009)
PNASl, vol.108, no.51, pp.20713~20718(2011)*

Also Published As

Publication number Publication date
US9968639B2 (en) 2018-05-15
AU2013280698A1 (en) 2015-01-22
CN104640979B (zh) 2021-05-04
CA2876677C (en) 2021-09-07
KR20190141263A (ko) 2019-12-23
WO2014004341A1 (en) 2014-01-03
IL266965A (en) 2019-07-31
JP2018193394A (ja) 2018-12-06
PT2864473T (pt) 2019-09-27
DK2864473T3 (da) 2019-09-23
JP6386453B2 (ja) 2018-09-05
JP2015522281A (ja) 2015-08-06
EP3611255A1 (en) 2020-02-19
IL266965B (en) 2021-08-31
IL236346A0 (en) 2015-02-26
EA201590088A1 (ru) 2015-04-30
SG11201408717XA (en) 2015-02-27
IL236346B (en) 2019-06-30
EA033954B1 (ru) 2019-12-13
EP2864473A1 (en) 2015-04-29
CA2876677A1 (en) 2014-01-03
BR112014031676A2 (pt) 2017-10-31
EP2864473B1 (en) 2019-08-21
US20150231181A1 (en) 2015-08-20
CN104640979A (zh) 2015-05-20
KR20150036059A (ko) 2015-04-07
AU2013280698B2 (en) 2019-01-17
JP6856586B2 (ja) 2021-04-07
EA201992135A1 (ru) 2020-02-05
IN2015DN00281A (enExample) 2015-06-12
CN113265370A (zh) 2021-08-17
KR102174581B1 (ko) 2020-11-06
US20130344594A1 (en) 2013-12-26
AU2019202085A1 (en) 2019-04-18
US9474772B2 (en) 2016-10-25
ES2745704T3 (es) 2020-03-03

Similar Documents

Publication Publication Date Title
KR102058259B1 (ko) 인슐린 의존성 당뇨병의 치료에 유용한 줄기 세포 및 췌장 세포
US8415153B2 (en) Differentiation and enrichment of islet-like cells from human pluripotent stem cells
US9115342B2 (en) Method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
JP6581655B2 (ja) 多能性幹細胞由来ケラチノサイトの生成およびケラチノサイト培養の維持
CN109486751B (zh) 用于无饲养细胞培养牛和猪的精原干细胞的方法
US20040191901A1 (en) Insulin producing cells derived from human embryonic stem cells
EP2556147B1 (en) Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
EP1446476A4 (en) Endothelial cells derived from embryonic stem cells
US20060084167A1 (en) Formation of Hybrid Cells by Fusion of Lineage Committed Cells with Stem Cells
CN113528441A (zh) 快速高效的临床级色素上皮细胞诱导方法、试剂盒及应用
Van Vranken et al. The differentiation of distal lung epithelium from embryonic stem cells
US20050244960A1 (en) Preparation of type II pneumocytes from stem cells
EP4349966A1 (en) Method for constructing alveolar organoid using induced pluripotent stem cells derived from alveolar cells
EA045078B1 (ru) Стволовые клетки и клетки поджелудочной железы, используемые для лечения инсулинозависимого сахарного диабета
CN116783287A (zh) 从干细胞诱导生成视网膜外层细胞的方法及包含通过该方法生成的细胞的用于预防或治疗视网膜疾病的组合物
HK1182134B (en) Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof
HK1182134A (en) Chondrogenic progenitor cells, protocol for derivation of cells and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 7